| 0.7002 -1.24 (-63.91%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.09 |
1-year : | 2.88 |
| Resists | First : | 1.79 |
Second : | 2.47 |
| Pivot price | 2.03 |
|||
| Supports | First : | 0.69 |
Second : | 0.57 |
| MAs | MA(5) : | 1.8 |
MA(20) : | 2.07 |
| MA(100) : | 3.24 |
MA(250) : | 8.76 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 35.2 |
| RSI | RSI(14): 21.1 |
|||
| 52-week | High : | 44.79 | Low : | 0.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NBY ] has closed below the lower bollinger band by 40.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NBY ] is to continue within current trading range. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.88 - 0.89 | 0.89 - 0.89 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Fri, 26 Jul 2024
Why NovaBay Pharmaceuticals (NBY) Stock Is Down 60% - Benzinga
Fri, 26 Jul 2024
NovaBay Pharmaceuticals announces public offering of common stock and warrants - Investing.com
Fri, 26 Jul 2024
Dow Surges 550 Points; Headline PCE Price Index Falls To 2.5% - Benzinga
Fri, 26 Jul 2024
NovaBay Pharmaceuticals announces pricing of $3.5M underwritten offering - MSN
Fri, 26 Jul 2024
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering - Yahoo Finance
Fri, 26 Jul 2024
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 93 (K) |
| EPS | -7.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.76 |
| Profit Margin | -93.9 % |
| Operating Margin | -34.2 % |
| Return on Assets (ttm) | -24.5 % |
| Return on Equity (ttm) | -132 % |
| Qtrly Rev. Growth | -14.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.24 |
| EBITDA (p.s.) | -1.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.9 |
| Price to Sales | 0.31 |
| Price to Cash Flow | -0.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|